Toll Free: 1-888-928-9744
Published: Feb, 2014 | Pages:
47 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Compugen Ltd. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Compugen Ltd. - Product Pipeline Review - 2014', provides an overview of the Compugen Ltd.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Compugen Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Compugen Ltd. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Compugen Ltd.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Compugen Ltd.'s pipeline products Reasons to buy - Evaluate Compugen Ltd.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Compugen Ltd. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Compugen Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Compugen Ltd. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Compugen Ltd. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Compugen Ltd. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Compugen Ltd. Snapshot 6 Compugen Ltd. Overview 6 Key Information 6 Key Facts 6 Compugen Ltd. - Research and Development Overview 7 Key Therapeutic Areas 7 Compugen Ltd. - Pipeline Review 11 Pipeline Products by Stage of Development 11 Pipeline Products - Monotherapy 12 Pipeline Products - Out-Licensed Products 13 Out-Licensed Products/Combination Treatment Modalities 14 Compugen Ltd. - Pipeline Products Glance 15 Compugen Ltd. - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Discovery Products/Combination Treatment Modalities 17 Compugen Ltd. - Drug Profiles 18 CGEN-15001 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 CGEN-15021 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 CGEN-15031 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 CGEN-15051 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 CGEN-15091 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 CGEN-25007 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 CGEN-25008 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 CGEN-25009 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 CGEN-25068 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 CGEN-856S 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 CGEN-857 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Fusion Proteins For Autoimmune And Inflammatory Diseases 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Monoclonal Antibody Targeting CGEN-15001T For Cancer 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Monoclonal Antibody Targeting CGEN-15022 For Cancer 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Monoclonal Antibody Targeting CGEN-671 For Epithelial Tumor 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Monoclonal Antibody Targeting CGEN-928 For Multiple Myeloma 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Antibody Drug Conjugate Program 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Monoclonal Antibody For Epithelial Cancers 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Monoclonal Antibody Targeting CGEN-15049 For Cancer 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Compugen Ltd. - Pipeline Analysis 38 Compugen Ltd. - Pipeline Products by Target 38 Compugen Ltd. - Pipeline Products by Molecule Type 39 Compugen Ltd. - Pipeline Products by Mechanism of Action 40 Compugen Ltd. - Recent Pipeline Updates 41 Compugen Ltd. - Dormant Projects 44 Compugen Ltd. - Locations And Subsidiaries 45 Head Office 45 Other Locations & Subsidiaries 45 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 47 Disclaimer 47
List of Tables Compugen Ltd., Key Information 6 Compugen Ltd., Key Facts 6 Compugen Ltd. - Pipeline by Indication, 2014 9 Compugen Ltd. - Pipeline by Stage of Development, 2014 11 Compugen Ltd. - Monotherapy Products in Pipeline, 2014 12 Compugen Ltd. - Out-Licensed Products in Pipeline, 2014 13 Compugen Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2014 14 Compugen Ltd. - Preclinical, 2014 15 Compugen Ltd. - Discovery, 2014 17 Compugen Ltd. - Pipeline by Target, 2014 38 Compugen Ltd. - Pipeline by Molecule Type, 2014 39 Compugen Ltd. - Pipeline Products by Mechanism of Action, 2014 40 Compugen Ltd. - Recent Pipeline Updates, 2014 41 Compugen Ltd. - Dormant Developmental Projects,2014 44 Compugen Ltd., Subsidiaries 45
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.